TY - JOUR
T1 - ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer
AU - Li, Haiqing
AU - Price, Douglas K.
AU - Figg, William D.
PY - 2007/6
Y1 - 2007/6
N2 - The conversion from E-cadherin to N-cadherin has been observed in several human cancer types, including prostate cancer, with more homogenous expression of N-cadherin detected in high-grade prostate tumors. N-cadherin, in vitro, has been shown to promote cell mobility, migration and invasion of several cancer cell lines, indicating the possibility of N-cadherin as a molecular target of cancer therapy. Herein, we examined the potential of an N-cadherin inhibitor, ADH1, in reducing tumor angiogenesis ex vivo and delaying tumor progression in vivo. Our data demonstrate that ADH1, at the dosages evaluated, does not display either antiangiogenic activity in a rat aortic ring assay or antitumor potential in a PC3 subcutaneous xenograft tumor model. We detecteded cytotoxic activity in human umbilical vein endothelial cells, PC3, and Tsu-Pr1 cells, when ADH1 exposure was evaluated at 500 μmol/l or above.
AB - The conversion from E-cadherin to N-cadherin has been observed in several human cancer types, including prostate cancer, with more homogenous expression of N-cadherin detected in high-grade prostate tumors. N-cadherin, in vitro, has been shown to promote cell mobility, migration and invasion of several cancer cell lines, indicating the possibility of N-cadherin as a molecular target of cancer therapy. Herein, we examined the potential of an N-cadherin inhibitor, ADH1, in reducing tumor angiogenesis ex vivo and delaying tumor progression in vivo. Our data demonstrate that ADH1, at the dosages evaluated, does not display either antiangiogenic activity in a rat aortic ring assay or antitumor potential in a PC3 subcutaneous xenograft tumor model. We detecteded cytotoxic activity in human umbilical vein endothelial cells, PC3, and Tsu-Pr1 cells, when ADH1 exposure was evaluated at 500 μmol/l or above.
KW - ADH1
KW - Angiogenesis
KW - N-cadherin
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=34247096609&partnerID=8YFLogxK
U2 - 10.1097/CAD.0b013e328020043e
DO - 10.1097/CAD.0b013e328020043e
M3 - Article
C2 - 17414625
AN - SCOPUS:34247096609
SN - 0959-4973
VL - 18
SP - 563
EP - 568
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
IS - 5
ER -